Abstract 1600P
Background
Sarcopenia is a disorder that causes muscle mass and strength loss, which can result in diminished mobility and functional limits. Depression and a bad assessment of one's own health are common results among cancer patients. As a result, this study aimed to look at the association between sarcopenia, depression, and health perception.
Methods
Cancer patients were the subject of a retrospective study from January to April 2023. The study included 150 patients who had different forms of a verified cancer diagnosis. These individuals were admitted to Mayo Hospital's Palliative Care Cancer Department. The presence of depressive symptoms was assessed using the Patient Health Questionnaire (PHQ-9). SARC-F was used to measure all the five dimensions of sarcopenia. To examine self-perceived health, a self-report questionnaire was used. The relationships between sarcopenia, depression, and health perception were investigated using correlation analysis.
Results
We observed a significant and positive association between depression and the dimensions of sarcopenia. Specifically, we found a positive correlation between depression and SARC1=Strength (r = 0.378, p<0.01), SARC2=Assistance in walking (r = 0.390, p<0.01), SARC3=Rise from a chair (r = 0.488, p<0.01), and SARC4=Climb stairs (r = 0.392, p<0.01). However, we found a positive but insignificant relationship between depression and SARC5=Falls (r = 0.150, p>0.05). In addition, we discovered that patients' perception of poor health was correlated with depression (r = -0.391, p<0.01), SARC2=Assistance in walking (r = -0.235, p<0.01), SARC3=Rise from a chair (r = -0.259, p<0.01), and SARC4=Climb stairs (r = -0.277, p<0.01). However, we did not find a significant relationship between health perception and two dimensions of sarcopenia (i.e., SARC1=Strength and SARC5=Falls).
Conclusions
Sarcopenia adversely affects the physical and mental health of cancer patients. They feel depressed and perceive their health as bad which imparts a negative impact on the outcome of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05